DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

Prodessa Pharmaceuticals

www.prodessapharma.comStockholm, Sweden
36 profile visits

About

Prodessa Pharmaceuticals is a Stockholm-based animal health company, founded in 2025 by researchers from the Karolinska Institutet, Sweden, and SUNY Upstate New York, USA. We are driven by our mission, that through dedication, innovation and cutting-edge research, be on the frontier in the fight against pet obesity.  

Our flagship molecule, K161, a pan-SHIP1/2 inhibitor, reduces chronic inflammation and improves oxidative metabolism to promote leanness and preserve muscle mass.  In preclinical small animal trials, K161 achieved a 20–25% weight reduction without appetite suppression, change in diet or enhanced physical activity.

We are now looking for partners to join our journey.

Social media

Areas of Activity

Biotech/BiopharmaPharmaStart-up (<12 months incorp.)

Representatives

Benedict Chambers

CEO

Prodessa Pharmaceuticals

Anne Liljander

Prodessa Pharmaceuticals